Japanese encephalitis virus vaccine cost

Japanese Encephalitis VIS. Minus Related Pages. VIS in other languages external icon More information about japanese encephalitis vaccination. Why get vaccinated? Japanese encephalitis occurs mainly in many parts of Asia and the Western Pacific, particularly in rural areas. It is spread through the bite of an infected mosquito.

It does not spread from person to person. Risk is very low for most travelers. It is higher for people living in areas where the disease is common, or for people traveling there for long periods of time. Others might have symptoms as mild as a fever and headache, or as serious as encephalitis swelling of the brain. A person with encephalitis can experience fever, neck stiffness, seizures, and coma. About 1 person in 4 with encephalitis dies. It is believed that infection in a pregnant woman could harm her unborn baby.

On This Page. JE vaccine Talk with your health care provider Risks of a vaccine reaction What if there is a serious problem? How can I learn more? JE vaccine. Japanese encephalitis vaccine is approved for people 2 months of age and older.

It is recommended for people who: Plan to live in a country where JE occurs, Plan to visit a country where JE occurs for long periods e. It should also be considered for travelers spending less than one month in a country where JE occurs, if they: Will visit rural areas and have an increased risk for mosquito bites, Are not sure of their travel plans.

Other drugs may interact with Japanese encephalitis virus vaccine, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Your doctor or pharmacist can provide more information about this vaccine.

Additional information is available from your local health department or the Centers for Disease Control and Prevention. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Every effort has been made to ensure that the information provided by Cerner Multum, Inc.

Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides.

The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. All insurance policies and group benefit plans contain exclusions and limitations.

For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico. Selecting these links will take you away from Cigna. Cigna may not control the content or links of non-Cigna websites.

Overview Medicare Coverage Options. Broker Resources. Individuals and Families. Health and Wellness. Wellness Library.

Japanese encephalitis virus vaccine SA What is the most important information I should know about this vaccine? Kansai Iji. Japanese encephalitis. In: Monath TP, editor.

The arboviruses: epidemiology and ecology. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology.

Japanese encephalitis and West Nile viruses. Current Topics in Microbiology and Immunology. Berlin: Springer; Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent.

Am J Trop Med Hyg. Biological activities of the structural proteins of Japanese encephalitis virus. Acta Virol. Oya A. Immunity and prediction of epidemic in Japanese encephalitis. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case—control study.

BMC Infect Dis. Yu Y Development of Japanese encephalitis attenuated live vaccine virus SA and its charcteristics. J Virol. Genetic determinants of Japanese encephalitis virus vaccine strain SA that govern attenuation of virulence in mice. The yellow fever 17D vaccine virus as a vector for the expression of foreign proteins: development of new live flavivirus vaccines.

Mem Inst Oswaldo Cruz. The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector. Braz J Med Biol Res. Recombinant, chimaeric live, attenuated vaccine ChimeriVax incorporating the envelope genes of Japanese encephalitis SA virus and the capsid and nonstructural genes of yellow fever 17D virus is safe, immunogenic and protective in non-human primates.

Japanese Encephalitis Vaccine. Acta Paediatr Jpn. Kitaoka M. Host reactions following vaccination against Japanese encephalitis with special reference to neurological complications. Immunization for Japanese encephalitis. Tokyo: Igaku Shoin Ltd; Physical reactions following vaccination against Japanese encephalitis with special reference to neurological complications. Adv Neurol Sci. Centers for Disease Control and Prevention.

Inactivated Japanese encephalitis virus vaccine. Recommendations of the advisory committee on immunization practices ACIP. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: a systematic review and meta-analysis. Human Vaccines Immunother. Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive to month-olds: multicenter randomized controlled trial.

Pediatr Infect Dis J. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Safety of a live-attenuated Japanese encephalitis virus vaccine SA for children.

World Health Organization. Newly accessible Japanese encephalitis vaccine will make saving children easier in developing countries. Media Centre j WHO. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine JE-CV in comparison with SA vaccine in children in the Republic of Korea. Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka.

Ceylon Med J. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. The immunogenicity and safety of the live-attenuated SA Japanese encephalitis vaccine given with a two-dose primary schedule in children.

J Korean Med Sci. A completed field trial for an evaluation of the effectiveness of mouse-brain Japanese encephalitis vaccine. Immunogenicity of JE Nakayama and Beijing-1 vaccines.

The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine—results from 30 years experience in Taiwan. Gowal D, Tahlan AK. Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian J Med Res. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis JE vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.

Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain. Clin Vaccine Immunol. Efficacy of single-dose SA 14—14—2 vaccine against Japanese encephalitis: a case control study. Effectiveness of live-attenuated Japanese encephalitis vaccine SA : a case-control study.

Effectiveness of one dose of SA vaccine against Japanese encephalitis. Solomon T. Flavivirus encephalitis. Epidemiol Rev. Clinical and immunological risk factors for severe disease in Japanese encephalitis.

Proinflammatory cytokines and chemokines in humans with Japanese encephalitis.